BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
📌TL;DR
EyePoint's Duravyu did not meet the LUGANO primary endpoint of visual acuity change versus aflibercept in the full dataset; excluding 9 of 211 patients with vision loss the company attributes to causes other than wet AMD, it was non inferior (nominal p=0.0096). LUCIA reads out in the fourth quarter. Shares were about 70 percent lower premarket, per RTTNews.
AstraZeneca discontinued the 895 patient Phase 3 eVOLVE-Lung02 trial of volrustomig plus chemotherapy after the data monitoring committee said it was unlikely to meet progression free or overall survival in PD-L1 negative first line lung cancer.
Two other AstraZeneca Phase 3 lung cancer trials met their primary endpoints the same day: HUTCHMED's 338 patient SAFFRON trial of Orpathys plus Tagrisso (PFS and OS) and Daiichi Sankyo's DESTINY-Lung04 trial of Enhertu in first line HER2 mutant disease (PFS).
Slate Medicines will reverse merge into Fulcrum Therapeutics with a $245 million private placement led by Frazier; Fulcrum holders keep about 5 percent and receive an estimated $270 million dividend, and the company will trade as SLTE after a fourth quarter close.
Eli Lilly signed an ion channel discovery deal with OmniAb: undisclosed upfront, up to $370 million in milestones, and tiered royalties.
Johnson and Johnson returned the prizlon-cel CAR T program to AbelZeta, per BioSpace, and Celcuity is waiting on FDA review of a second manufacturing site before Revtorpyk ships late this quarter, per Endpoints News.
⚡ Executive Takeaway
Day two of the ledger is about what a public listing is worth once the binary inside it is gone. Fulcrum dropped its lead drug in June and sold its listing on Monday for about 5 percent of a new company plus a $270 million dividend. Skye arrived at Friday's Fibrx deal with a listing and no cash and kept 5.38 percent, with no dividend. Same week, same structure, same slice of the equity, and the only variable that moved the price was net cash. The listing itself cleared at roughly zero both times.
That is the number to carry into every reverse merger this year, and Endpoints counts 17 of them already. The shell is not the asset. The cash is the asset, and the specialist syndicate writing the $245 million check is buying a Nasdaq ticker as a free option on top of it. EyePoint is the same lesson from the other side: a listed company that held its own binary and watched nine patients redefine it before the market opened. Holders of shells and holders of coin flips are learning the same price. 👉 Read Full Analysis
👁️ Ophthalmology
EyePoint's six month insert missed on the full population and passed on 202 patients, and the FDA will get to pick which one counts. EYPT
Duravyu 2.7 mg dosed every six months did not achieve non inferiority to on label 2 mg aflibercept on the primary endpoint, average change in best corrected visual acuity at weeks 52 and 56, in the full LUGANO dataset. EyePoint says an asymmetric cohort of 9 of 211 patients (4 percent) lost 15 or more letters for reasons unrelated to wet AMD, and that with them excluded the insert was non inferior with a nominal p value of 0.0096. The prespecified secondaries went the company's way: a 42 percent cut in treatment burden, 76 percent of patients supplement free through week 32, 79 percent needing one or no supplemental injection through week 56, and a clean safety table with no vasculitis or severe inflammation. LUCIA, the second pivotal, reads out in the fourth quarter and EyePoint still plans an NDA in the first half of 2027. RTTNews put the premarket move at about 70 percent, from $14.75 to $4.48. The regulatory question is simple to state and hard to answer: does a full dataset miss rescued by an ad hoc exclusion count as one of two adequate and well controlled trials. The Pro brief works through what nine patients do to a label.
🎯 Oncology
AstraZeneca killed a Phase 3, won two more, and reminded everyone what a big pharma binary looks like: absorbed before lunch. AZN | HCM
The independent data monitoring committee for eVOLVE-Lung02, 895 patients across 25 countries, concluded that volrustomig, AstraZeneca's PD-1 and CTLA-4 bispecific, plus chemotherapy was unlikely to beat pembrolizumab plus chemotherapy on either progression free or overall survival in first line lung cancer with PD-L1 below 1 percent, so the trial stops; cervical, head and neck, and mesothelioma Phase 3s continue. Hours later HUTCHMED said the 338 patient SAFFRON trial of Orpathys plus Tagrisso met both PFS and OS against chemotherapy in EGFR mutated, MET driven lung cancer after progression on Tagrisso, and Daiichi Sankyo said Enhertu met PFS in DESTINY-Lung04 against chemotherapy plus pembrolizumab in first line HER2 mutant disease. No effect sizes from any of the three; the wins are being saved for congresses. The pattern is worth naming: the two wins are precision subsets carved out of a resistant or rare population, and the loss was an attempt to beat Keytruda head on in a biomarker negative crowd. BioSpace filed the volrustomig result under a run of AstraZeneca setbacks that includes Wainua, Ultomiris, and elecoglipron.
💰 Reverse Mergers
Fulcrum's holders got a dividend and 5 percent for their listing; Skye's got 5.38 percent and no dividend. That gap is the whole market for shells. FULC
Slate Medicines will merge into Fulcrum Therapeutics alongside a $245 million oversubscribed private placement led by Frazier Life Sciences with Forbion, RA Capital, Deep Track, Foresite, OrbiMed, RTW, and Mingxin. Pre merger Fulcrum holders keep about 5.0 percent, subject to a net cash adjustment, and get an estimated $270 million dividend before closing; Fulcrum contributes about $20.3 million of net cash to the combined company. Slate's lead is SLTE-1009, a subcutaneous antibody blocking both PACAP and VIP for migraine prevention, in Phase 1 in Australia with data in mid 2027, and a PACAP, VIP, and CGRP bispecific behind it; runway runs into 2029 and the ticker becomes SLTE after a fourth quarter close. Slate launched from stealth in February with a $130 million Series A, per Fierce Biotech, so this is a six month old company buying a listing with someone else's money. Endpoints counts 17 reverse mergers completed in 2026, the most since 2018. Column five of the ledger, creation vehicles absorbing binaries wholesale, now has two entries in three business days, and the Pro brief prices the difference between them.
🧪 Deals
Lilly bought an option on an ion channel; Johnson and Johnson handed a CAR T back. Both are ledger entries. LLY | JNJ
OmniAb signed a global collaboration and license agreement with Eli Lilly for a new ion channel discovery program: an undisclosed upfront, up to $370 million in research, development, and commercial milestones, and tiered royalties, with the target and modality undisclosed. Almost all of that number is contingent, which is how Lilly has been buying early biology this month, from Sangamo's platforms for $50 million cash last week to this. In the other direction, Johnson and Johnson has returned prizloncabtagene autoleucel, the bispecific CAR T for large B cell lymphoma it licensed from AbelZeta in 2023, to its originator, per BioSpace, which puts the original upfront at $245 million and notes the asset quietly left J&J's pipeline slides in April. Two more columns for the count: contingent consideration written, and a binary returned to sender.
📋 Quick Hits
Celcuity is awaiting FDA review of a second manufacturing facility before Revtorpyk ships late this quarter, per Endpoints News, which put the review at two to four months; the company's own release says only that shipments begin late in the third quarter. The factory, not the drug, again.
Regeneron terminated the Phase 1/2a TITAN trial of REGN7041, an anti CD3 antibody for non infectious uveitis, after reviewing a safety event whose cause it could not identify, per Fierce Biotech.
Endpoints reports that longer follow up accompanying ivonescimab's newest Chinese approval showed a smaller PFS benefit than the interim analysis, about a 28 percent risk reduction versus about 40 percent; Summit's November 14 FDA date is unchanged. SMMT
The FDA's summary basis for approval shows Vera's Trutakna held kidney function flat through 52 weeks in ORIGIN 3, per BioSpace, with the agency calling the eGFR data promising but not definitive. VERA
Johnson and Johnson's Monarch bronchoscopy robot cleared an AI software update, and the FDA named hypertension software maker Cadence the second participant in its TEMPO digital health pilot after Dexcom, per MedTech Dive.
Seven large drugmakers plus PhRMA and BIO filed comments backing the USTR's Section 301 probe of Germany's drug pricing rules, per Endpoints News.
Fierce Biotech reports two previously undisclosed deaths in Chinese investigator initiated gene therapy trials, including a HuidaGene Duchenne study; China's Order 818 took effect in May with GMP and reporting requirements. Read against BINSA and the China licensing thread.
📖 In Today's Full Analysis
Be sure to read the full article for all the details, including:
The full LUGANO endpoint table, including the ad hoc analysis and what the FDA typically does with post hoc exclusions
AstraZeneca's three trial scorecard: eVOLVE-Lung02, SAFFRON, and DESTINY-Lung04 side by side
The Slate and Fulcrum term sheet next to Fibrx: ownership, dividend, net cash, runway
The updated binary ledger with Monday's five new entries and the Lilly OmniAb and J&J AbelZeta terms
🔒 BioMed Nexus Pro
In Today's Pro Brief...
🧠 What nine patients do to a label: how a full dataset miss and an ad hoc pass get read at the FDA, and the one LUCIA outcome that still gets Duravyu approved
📊 AstraZeneca's portfolio day, and why the loss and the two wins point the same direction for every bispecific with a November decision date
💰 The price of a shell: what Fulcrum's dividend and Skye's zero tell you about column five of the ledger, and how to read the 17 reverse mergers behind them
🎯 Plus the catalysts to watch into Friday's full calendar
Two shells sold for the same slice of equity and different piles of cash, one insert missed on the analysis that counts, and a big pharma took a Phase 3 loss before lunch and did not blink. The ledger is filling in faster than we expected. What are you watching? Reply to this email.
Sponsorship slots for 2026 are limited. See packages and pricing →
NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →